Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 144


A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.

Zuo Y, Shi Y, Li X, Teng Y, Pan Z.

Sci Rep. 2015 Nov 4;5:16136. doi: 10.1038/srep16136.


Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Stephens DM, Spurgeon SE.

Ther Adv Hematol. 2015 Oct;6(5):242-52. doi: 10.1177/2040620715592569. Review.


Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background.

Elvers I, Turner-Maier J, Swofford R, Koltookian M, Johnson J, Stewart C, Zhang CZ, Schumacher SE, Beroukhim R, Rosenberg M, Thomas R, Mauceli E, Getz G, Palma FD, Modiano JF, Breen M, Lindblad-Toh K, Alföldi J.

Genome Res. 2015 Nov;25(11):1634-45. doi: 10.1101/gr.194449.115. Epub 2015 Sep 16.


Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Bernard S, Goldwirt L, Amorim S, Brice P, Brière J, de Kerviler E, Mourah S, Sauvageon H, Thieblemont C.

Blood. 2015 Oct 1;126(14):1695-8. doi: 10.1182/blood-2015-05-647834. Epub 2015 Aug 3.


Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.

de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E.

Pharmacol Res Perspect. 2015 Aug;3(4):e00156. doi: 10.1002/prp2.156. Epub 2015 Jun 24.


A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Tucker DL, Rule SA.

Ther Clin Risk Manag. 2015 Jun 23;11:979-90. doi: 10.2147/TCRM.S73559. eCollection 2015. Review.


Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection.

Fouad M, Helvenstein M, Blankert B.

J Anal Methods Chem. 2015;2015:215128. doi: 10.1155/2015/215128. Epub 2015 May 25.


The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.


Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.

Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, Morita R.

Nat Commun. 2015 Jun 10;6:7360. doi: 10.1038/ncomms8360.


Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.

Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R.

J Hematol Oncol. 2015 May 29;8:60. doi: 10.1186/s13045-015-0157-x.


Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J.

Nat Chem Biol. 2015 Jul;11(7):525-31. doi: 10.1038/nchembio.1817. Epub 2015 May 25.


The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Liu Y, Ye J, Shin Ogawa L, Inoue T, Huang Q, Chu J, Bates RC, Ying W, Sonderfan AJ, Rao PE, Zhou D.

PLoS One. 2015 May 14;10(5):e0127361. doi: 10.1371/journal.pone.0127361. eCollection 2015.


Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

Rex EB, Kim S, Wiener J, Rao NL, Milla ME, DiSepio D.

J Biomol Screen. 2015 Aug;20(7):876-86. doi: 10.1177/1087057115585724. Epub 2015 May 6.


Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.

Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.

Oncotarget. 2015 Jun 20;6(17):15122-36.


Signal transduction and chemotaxis in mast cells.

Draber P, Halova I, Polakovicova I, Kawakami T.

Eur J Pharmacol. 2015 May 2. pii: S0014-2999(15)00397-0. doi: 10.1016/j.ejphar.2015.02.057. [Epub ahead of print]


The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.

Chon HJ, Bae KJ, Lee Y, Kim J.

Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015.


Switching immune signals on and off.

Chu N, Cole PA.

Elife. 2015 Apr 2;4. doi: 10.7554/eLife.07204. No abstract available.


Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V.

Clin Cancer Res. 2015 Aug 15;21(16):3705-15. doi: 10.1158/1078-0432.CCR-14-2809. Epub 2015 Mar 31.


Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.

Oncotarget. 2015 Apr 20;6(11):8750-9.


Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H.

Blood. 2015 May 21;125(21):3236-45. doi: 10.1182/blood-2014-10-605808. Epub 2015 Mar 20. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk